{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:32:05Z","timestamp":1784089925602,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":173,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Japan Tabacco Inc","award":["148228"],"award-info":[{"award-number":["148228"]}]},{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","award":["150475"],"award-info":[{"award-number":["150475"]}],"id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s13311-022-01328-2","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T13:03:31Z","timestamp":1671627811000},"page":"546-563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparison of Solriamfetol and Modafinil on Arousal and Anxiety-Related Behaviors in Narcoleptic Mice"],"prefix":"10.1016","volume":"20","author":[{"given":"Noriaki","family":"Sakai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1007\/s13311-022-01328-2_bib1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41582-019-0226-9","article-title":"Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment","volume":"15","author":"Bassetti","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-022-01328-2_bib2","first-page":"855","article-title":"Narcolepsy: genetics, immunology, and pathophysiology, in principles and practice of sleep medicine, 6th edition","author":"Mignot","year":"2015"},{"issue":"19","key":"10.1007\/s13311-022-01328-2_bib3","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1523\/JNEUROSCI.0073-14.2014","article-title":"Conditional ablation of orexin\/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function","volume":"34","author":"Tabuchi","year":"2014","journal-title":"J Neurosci"},{"issue":"2","key":"10.1007\/s13311-022-01328-2_bib4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0896-6273(01)00293-8","article-title":"Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity","volume":"30","author":"Hara","year":"2001","journal-title":"Neuron"},{"issue":"9","key":"10.1007\/s13311-022-01328-2_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsy116","article-title":"Partial ablation of the orexin field induces a sub-narcoleptic phenotype in a conditional mouse model of orexin neurodegeneration","volume":"41","author":"Black","year":"2018","journal-title":"Sleep"},{"key":"10.1007\/s13311-022-01328-2_bib6","series-title":"Principles and Practice of Sleep Medicine","first-page":"446","article-title":"Wake-promoting medications: basic mechanisms and pharmacology","author":"Nishino","year":"2015"},{"key":"10.1007\/s13311-022-01328-2_bib7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fneur.2013.00139","article-title":"Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions","volume":"4","author":"Wisor","year":"2013","journal-title":"Front Neurol"},{"issue":"2","key":"10.1007\/s13311-022-01328-2_bib8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1124\/jpet.118.248120","article-title":"Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor","volume":"366","author":"Baladi","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"10.1007\/s13311-022-01328-2_bib9","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/npp.2009.3","article-title":"How to keep the brain awake? The complex molecular pharmacogenetics of wake promotion","volume":"34","author":"Hasan","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1007\/s13311-022-01328-2_bib10","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.sleep.2015.05.013","article-title":"Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy","volume":"16","author":"Bogan","year":"2015","journal-title":"Sleep Med"},{"issue":"7","key":"10.1007\/s13311-022-01328-2_bib11","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.5665\/sleep.5968","article-title":"Effect of oral JZP-110 (ADX-N05) on wakefulness and sleepiness in adults with narcolepsy: a phase 2b study","volume":"39","author":"Ruoff","year":"2016","journal-title":"Sleep"},{"issue":"3","key":"10.1007\/s13311-022-01328-2_bib12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ana.25423","article-title":"A randomized study of solriamfetol for excessive sleepiness in narcolepsy","volume":"85","author":"Thorpy","year":"2019","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01328-2_bib13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.sleep.2019.11.1250","article-title":"Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy","volume":"67","author":"Emsellem","year":"2020","journal-title":"Sleep Med"},{"issue":"11","key":"10.1007\/s13311-022-01328-2_bib14","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1164\/rccm.201806-1100OC","article-title":"Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3). A randomized controlled trial","volume":"199","author":"Schweitzer","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1007\/s13311-022-01328-2_bib15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.chest.2021.02.033","article-title":"Randomized controlled trial of solriamfetol for excessive daytime sleepiness in OSA: an analysis of subgroups adherent or nonadherent to OSA treatment","volume":"160","author":"Schweitzer","year":"2021","journal-title":"Chest"},{"issue":"1","key":"10.1007\/s13311-022-01328-2_bib16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.expneurol.2009.01.015","article-title":"Specificity of direct transition from wake to REM sleep in orexin\/ataxin-3 transgenic narcoleptic mice","volume":"217","author":"Fujiki","year":"2009","journal-title":"Exp Neurol"},{"issue":"1","key":"10.1007\/s13311-022-01328-2_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5665\/sleep\/32.1.111","article-title":"A consensus definition of cataplexy in mouse models of narcolepsy","volume":"32","author":"Scammell","year":"2009","journal-title":"Sleep"},{"issue":"5","key":"10.1007\/s13311-022-01328-2_bib18","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/npp.2017.260","article-title":"Too depressed to swim or too afraid to stop? A reinterpretation of the forced swim test as a measure of anxiety-like behavior","volume":"43","author":"Anyan","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1007\/s13311-022-01328-2_bib19","first-page":"177","article-title":"Modafinil for narcolepsy: systematic review and meta-analysis","volume":"16","author":"Golicki","year":"2010","journal-title":"Med Sci Monit"},{"issue":"1","key":"10.1007\/s13311-022-01328-2_bib20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/00912709922007534","article-title":"A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers","volume":"39","author":"Wong","year":"1999","journal-title":"J Clin Pharmacol"},{"issue":"1\u20132","key":"10.1007\/s13311-022-01328-2_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0014-2999(01)01578-3","article-title":"Effects of chronically administered venlafaxine on 5-HT receptor activity in rat hippocampus and hypothalamus","volume":"436","author":"Gur","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1007\/s13311-022-01328-2_bib22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF02244337","article-title":"Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers","volume":"113","author":"Mignot","year":"1993","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1007\/s13311-022-01328-2_bib23","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/sleep\/16.8.706","article-title":"Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds","volume":"16","author":"Nishino","year":"1993","journal-title":"Sleep"},{"issue":"34","key":"10.1007\/s13311-022-01328-2_bib24","doi-asserted-by":"crossref","first-page":"8462","DOI":"10.1523\/JNEUROSCI.1819-08.2008","article-title":"Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil","volume":"28","author":"Qu","year":"2008","journal-title":"J Neurosci"},{"issue":"7","key":"10.1007\/s13311-022-01328-2_bib25","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/npp.2011.23","article-title":"Dopamine receptor mediation of the exploratory\/hyperactivity effects of modafinil","volume":"36","author":"Young","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"8 Suppl","key":"10.1007\/s13311-022-01328-2_bib26","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1093\/sleep\/17.suppl_8.S107","article-title":"Modafinil: a double-blind multicentric study","volume":"17","author":"Billiard","year":"1994","journal-title":"Sleep"},{"issue":"10","key":"10.1007\/s13311-022-01328-2_bib27","first-page":"817","article-title":"Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs","volume":"18","author":"Shelton","year":"1995","journal-title":"Sleep"},{"issue":"4","key":"10.1007\/s13311-022-01328-2_bib28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.pbb.2010.03.006","article-title":"Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents","volume":"95","author":"Paterson","year":"2010","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1007\/s13311-022-01328-2_bib29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fnsys.2019.00028","article-title":"Dorsal striatal circuits for habits, compulsions and addictions","volume":"13","author":"Lipton","year":"2019","journal-title":"Front Syst Neurosci"},{"issue":"2","key":"10.1007\/s13311-022-01328-2_bib30","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1124\/jpet.108.146142","article-title":"Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil","volume":"329","author":"Zolkowska","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"22","key":"10.1007\/s13311-022-01328-2_bib31","doi-asserted-by":"crossref","first-page":"8620","DOI":"10.1523\/JNEUROSCI.20-22-08620.2000","article-title":"Hypothalamic arousal regions are activated during modafinil-induced wakefulness","volume":"20","author":"Scammell","year":"2000","journal-title":"J Neurosci"},{"issue":"2\u20133","key":"10.1007\/s13311-022-01328-2_bib32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejphar.2007.09.009","article-title":"Involvement of central histaminergic systems in modafinil-induced but not methylphenidate-induced increases in locomotor activity in rats","volume":"578","author":"Ishizuka","year":"2008","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1007\/s13311-022-01328-2_bib33","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsz031","article-title":"Genetic lesioning of histamine neurons increases sleep-wake fragmentation and reveals their contribution to modafinil-induced wakefulness","volume":"42","author":"Yu","year":"2019","journal-title":"Sleep"},{"issue":"Pt 6","key":"10.1007\/s13311-022-01328-2_bib34","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1113\/jphysiol.2010.203257","article-title":"L-Dopa activates histaminergic neurons","volume":"589","author":"Yanovsky","year":"2011","journal-title":"J Physiol"},{"key":"10.1007\/s13311-022-01328-2_bib35","doi-asserted-by":"crossref","first-page":"A329","DOI":"10.1093\/sleep\/zsac079.752","article-title":"Preclinical pharmacology of solriamfetol: potential mechanisms for wake promotion","volume":"45","author":"Gursahani","year":"2022","journal-title":"Sleep"},{"issue":"12","key":"10.1007\/s13311-022-01328-2_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/biom11121914","article-title":"5-HT receptors and temperature homeostasis","volume":"11","author":"Voronova","year":"2021","journal-title":"Biomolecules"},{"key":"10.1007\/s13311-022-01328-2_bib37","doi-asserted-by":"crossref","first-page":"6503162","DOI":"10.1155\/2016\/6503162","article-title":"Coping with the forced swim stressor: towards understanding an adaptive mechanism","volume":"2016","author":"de Kloet","year":"2016","journal-title":"Neural Plast"},{"issue":"7","key":"10.1007\/s13311-022-01328-2_bib38","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/sj.npp.1301534","article-title":"Modafinil: a review of neurochemical actions and effects on cognition","volume":"33","author":"Minzenberg","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1007\/s13311-022-01328-2_bib39","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.bbr.2016.12.007","article-title":"Increased anxiety but normal fear and safety learning in orexin-deficient mice","volume":"320","author":"Khalil","year":"2017","journal-title":"Behav Brain Res"},{"issue":"1","key":"10.1007\/s13311-022-01328-2_bib40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.genhosppsych.2009.08.007","article-title":"Anxiety and mood disorders in narcolepsy: a case-control study","volume":"32","author":"Fortuyn","year":"2010","journal-title":"Gen Hosp Psychiatry"},{"issue":"2","key":"10.1007\/s13311-022-01328-2_bib41","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2869.2007.00587.x","article-title":"Amygdala dysfunction in narcolepsy-cataplexy","volume":"16","author":"Khatami","year":"2007","journal-title":"J Sleep Res"},{"issue":"28","key":"10.1007\/s13311-022-01328-2_bib42","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1523\/JNEUROSCI.1211-05.2005","article-title":"State-dependent alterations in hippocampal oscillations in serotonin 1A receptor-deficient mice","volume":"25","author":"Gordon","year":"2005","journal-title":"J Neurosci"},{"issue":"1","key":"10.1007\/s13311-022-01328-2_bib43","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF02245254","article-title":"Minimal changes with long-term administration of anxiolytics on septal driving of hippocampal rhythmical slow activity","volume":"118","author":"Zhu","year":"1995","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1007\/s13311-022-01328-2_bib44","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.neuron.2019.08.006","article-title":"Hippocampal-prefrontal theta transmission regulates avoidance behavior","volume":"104","author":"Padilla-Coreano","year":"2019","journal-title":"Neuron"},{"issue":"6","key":"10.1007\/s13311-022-01328-2_bib45","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/sleep\/31.6.859","article-title":"Challenging sleep homeostasis in narcolepsy-cataplexy: implications for non-REM and REM sleep regulation","volume":"31","author":"Khatami","year":"2008","journal-title":"Sleep"},{"issue":"28","key":"10.1007\/s13311-022-01328-2_bib46","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1523\/JNEUROSCI.0586-04.2004","article-title":"Behavioral state instability in orexin knock-out mice","volume":"24","author":"Mochizuki","year":"2004","journal-title":"J Neurosci"},{"issue":"27","key":"10.1007\/s13311-022-01328-2_bib47","doi-asserted-by":"crossref","first-page":"E5464","DOI":"10.1073\/pnas.1700983114","article-title":"Hypocretin (orexin) is critical in sustaining theta\/gamma-rich waking behaviors that drive sleep need","volume":"114","author":"Vassalli","year":"2017","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01328-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01328-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923000971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923000971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01328-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:32:31Z","timestamp":1761805951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923000971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1878747923000971"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01328-2","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Solriamfetol and Modafinil on Arousal and Anxiety-Related Behaviors in Narcoleptic Mice","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01328-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}